There will be a LIVE Webcast on Wednesday, October 3, 2007 @ 2:00 PM ET; 11:00 AM PT on the topic of “Responding to Growing International Demand for Pre-Approval Access.”
The status of drugs in development is increasingly in the public eye both within and outside the US. As a result, pharmaceutical and biotechnology companies are faced with growing international demand from physicians and patients for drugs that are not yet approved in their home country. To meet this demand, companies can use Named Patient Programs to provide global, pre-approval access to their innovative medicines.
Named Patient Programs provide controlled access to drugs in response to requests by physicians on behalf of specific, or “named”, patients.
These programs are a legal and ethical way to manage patient access to medicines for unmet medical needs and can bring significant value to the sponsoring company in terms of physician and patient goodwill, opportunities for physician and pharmacist engagement and education, real-life data capture, product visibility, and revenue.
The participants in this Webcast will discuss the structure of Named Patient Programs, the medical and regulatory implications of these programs, the benefits to the sponsoring company, and strategies for launching and operating these programs. A case study will be presented, describing the benefits of a Named Patient Program to the sponsoring company, physicians, and patients.
For more information, or to register for free, please visit www.PharmExec.com/NamedPatient
